Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/07/23
Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate UpdateGlobeNewsWire • 02/21/23
Verona Pharma: Small Biotech Targeting $10Bn COPD Market With A Late Stage DrugSeeking Alpha • 02/07/23
Here's Why Momentum in Verona Pharma PLC American Depositary Share (VRNA) Should Keep goingZacks Investment Research • 12/22/22
Top-Notch Verona Pharma Scores A Win In COPD — And Hits A Four-Year HighInvestors Business Daily • 12/20/22
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPDGlobeNewsWire • 12/20/22
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPDGlobeNewsWire • 12/19/22
Here's Why Verona Pharma PLC American Depositary Share (VRNA) is a Great Momentum Stock to BuyZacks Investment Research • 12/05/22
Wall Street Analysts See a 95% Upside in Verona Pharma PLC American Depositary Share (VRNA): Can the Stock Really Move This High?Zacks Investment Research • 12/02/22
How Much Upside is Left in Verona Pharma PLC American Depositary Share (VRNA)? Wall Street Analysts Think 110%Zacks Investment Research • 11/15/22